Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
Synexa joins CEPI’s esteemed Central Lab Network to improve global epidemic preparedness
Capnopharm’s new CapnoPen is the first PIPAC nebulizer to obtain CE marking under the new MDR regulation 2017/745
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Aim of the agreement is to expand the full potential of Beren’s cyclodextrin technologies and their medicinal applications.
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
Product deliveries scheduled in Q3 of 2023
Continues to Expand its Presence in South India
Operating EBITDA increased by 21% to INR 181 crores in Q4 FY23
Subscribe To Our Newsletter & Stay Updated
